A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer

Journal of the National Cancer Institute

Volumn 83, Issue 5, 1991, Pages 355-358

  Rosenberg, Lynn ^a   Palmer, Julie R ^a   Zauber, Ann G ^b   Warshauer, M Ellen ^c   Stolley, Paul D ^d   Shapiro, Samuel ^a  

^a BOSTON UNIVERSITY   (United States)

^b Memorial Slone Kettering Cancer Center ^*  (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI INFLAMMATORY AGENTS, NON STEROIDAL; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; COLON TUMOR; FEMALE; HUMAN; MALE; RECTUM TUMOR; RISK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLONIC NEOPLASMS; FEMALE; HUMAN; MALE; RECTAL NEOPLASMS; RISK; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026417761     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/83.5.355     Document Type: Article

References (30)

1. Jaffe BM: Prostaglandins and cancer: An update. Prostaglandins 6:453–61, 1974
2. Craven PA, Saito R, DeRubertis FR: Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J Clin Invest 72:1365–1375, 1983
3. Lupulescu A: Enhancement of carcinogenesis by prostaglandins. Nature 272:634–636, 1978
4. Lynch NR, Castes M, Astoin M, et al: Mechanism of inhibition of tumour growth by aspirin and indomelhacin. Br J Cancer 38:503–512, 1978
5. Kudo T, Narisawa T, Abo S: Antitumor activity of indomelhacin on methylazoxy-methanol-induced large-bowel tumors in rats. Gann 71:260–264, 1980
6. Pollard M, Luckert PH: Indomelhacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 64:1323–1327, 1980
7. Narisawa T, Sato M, Tani M, et al: Inhibition of development of methylnitrosourea-in-duced rat colon tumors by indomethacin treatment. Cancer Res 41:1954–1957, 1981
8. Pollard M, Luckert PH: Treatment of chemically-induced intestinal cancers with indomethacin. Proc Soc Exp Biol Med 167:161–164, 1981
9. Pollard M, Luckert PH: Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. JNCI 70:1103–1105, 1983
10. Pollard M, Luckert PH, Schmidt MA: The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett 21:57–61, 1983
11. Narisawa T, Satoh M, Sano M, et al: Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis 4:1225–1227, 1983
12. Pollard M, Luckert PH: Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Lett 25:117–121, 1984
13. 2) against indomethacin. J Cancer Res Clin Oncol 108:239–242, 1984
14. Olsson NO, Caionard A, Martin MS, et al: Effect of indomethacin on the growth of colon cancer cells in syngeneic rats. Int J Immunopharmacol 6:329–334, 1984
15. Metzger U, Meier J, Uhlschmid G, et al: Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum 27:366–369, 1984
16. DeRubertis FR, Craven PA, Saito R: 16,16-Dimethyl prostaglandin E2 suppresses the increases in the proliferative activity of rat colonic epithelium induced by indomethacin and aspirin. Gastroenterology 89:1054–1063, 1985
17. Reddy BS, Maruyama H, Kelloff G: Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflam-matory drug, during different stages of rat colon tumor development. Cancer Res 47:5340–5346, 1987
18. Reddy BS, Nayini J, Tokumo K, et al: Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D, L-alpha-difluoromethylornithine, an omithine decarboxylase inhibitor, in diet. Cancer Res 50:2562–2568, 1990
19. Weisburger JH, Reddy BS, Joftes DL: Colo-rectal cancer. UICC Technical Report 19. Geneva: UICC, 1975
20. Slone D, Shapiro S, Miettinen OS: Case-control surveillance of serious illnesses attributable to ambulatory drug use. In Epidemiological Evaluation of Drugs (Colombo F, Shapiro S, Slone D, eds). Amsterdam: Elsevier/North Holland Biomed Press, 1977, pp 59–70
21. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748, 1959
22. Armitage P: Statistical Methods in Medical Research. New York: John Wiley, 1971, pp 319–320
23. Schottenfeld D, Winawer SJ: Large intestine. In Cancer Epidemiology and Prevention (Schottenfeld D, Fraumeni JF Jr, eds). Philadelphia: Saunders, 1982, pp 703–727
24. McMichael AJ, Potter JD: Do intrinsic sex differences in lower alimentary tract physiology influence the sex-specific risks of bowel cancer and other biliary and intestinal dis? Am J Epidemiol 118:620–627, 1983
25. Rosenberg L: Coffee and tea consumption in relation to the risk of large-bowel cancer: A review of epidemiologic studies. Cancer Lett 52:163–171, 1990
26. Waddell WR, Gerner RE, Reich MP: Nonsteroidal antiinflammatory drugs and tamox-ifen for desmoid tumors and carcinoma of the stomach. J Surg Oncol 22:197–211, 1983
27. Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24:83–87, 1983
28. Han T, Nemoto T, Ledesma EJ, et al: Enhancement of T lymphocyte proliferative response to mitogens by indomethacin in breast and colorectal cancer patients. Int J Im-munopharmacol 5:11–15, 1983
29. Steering Committee of the Physicians-Health Study Research Group: Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 321:129–135, 1989
30. Antiplatelet Trialists Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 296:320–331, 1988